Sun Pharma expects high single-digit top line growth in current fiscal

Sun Pharmaceutical Industries expects high single-digit top line growth in FY24 with total revenue at Rs 48,497 crore, led by Managing Director Dilip Shanghvi. The firm anticipates similar growth in FY25 with investments in product launches and R&D activities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dmnTsGo
via IFTTT